Hjem › Tykktarmskreft › North Carolina
Kliniske studier for Tykktarmskreft i North Carolina
20 studier for Tykktarmskreft søker deltakere på steder i North Carolina.
Byer i North Carolina
- Durham12 studier
- Charlotte5 studier
- Cary4 studier
- Winston-Salem3 studier
- Jacksonville3 studier
- Goldsboro3 studier
- Raleigh3 studier
Offisiell studietekst (engelsk)
Family Communications After Genetic Testing
- Southeastern Medical Oncology Center-Clinton, Clinton
- CaroMont Regional Medical Center, Gastonia
- Southeastern Medical Oncology Center-Goldsboro, Goldsboro
- og 2 flere
RekruttererFrivillige helsepersonell ønskes velkommen
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT07143487Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
- FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst
RekruttererFrivillige helsepersonell ønskes velkommen
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT07283939Distance-Based Exercise to Preserve Function and Prevent Disability
- Novant Health Cancer Institute - Kernersville, Kernersville
- Novant Health Cancer Institute - Mount Airy, Mount Airy
- Novant Health Forsyth Medical Center, Winston-Salem
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT07059884A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
- WakeMed Raleigh Campus ( Site 0094), Raleigh
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06997497A Study of PHN-012 in Patients With Advanced Solid Tumors
- PHN-012-001 Site, Durham
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 29. sep. 2026 · NCT07127874Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- Duke Cancer Center Cary, Cary
- Duke Cancer Center - Investigational Chemotherapy Service, Durham
- Duke Cancer Center, Durham
- og 2 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07222800A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
- Messino Cancer Center, Asheville
- The University of North Carolina At Chapel Hill, Chapel Hill
- Oncology Specialists of Charlotte, Charlotte
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 15. sep. 2026 · NCT07284849ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- UNC- Chapel Hill, Chapel Hill
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 14. sep. 2026 · NCT05059444A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)
- First Health of the Carolinas, Pinehurst
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 3. sep. 2026 · NCT07058012Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
- Southeastern Medical Oncology Center-Clinton, Clinton
- Southeastern Medical Oncology Center-Goldsboro, Goldsboro
- Southeastern Medical Oncology Center-Jacksonville, Jacksonville
Rekrutterer
Alder 45 til 70 · Alle kjønn · Oppdatert 2. sep. 2026 · NCT05080673Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
- Duke Cancer Center Cary, Cary
- UNC Health Cancer Care Cary, Cary
- Waverly Hematology Oncology, Cary
- og 22 flere
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 2. sep. 2026 · NCT05174169Shield Post-Approval Study Protocol
- Cary Gastroenterology Associates, Cary
- University of North Carolina at Chapel Hill, Chapel Hill
- University of North Carolina at Chapel Hill, Chapel Hill
- og 1 flere
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 45 til 81 · Alle kjønn · Oppdatert 7. aug. 2026 · NCT06880055Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- Xencor Investigative Site, Charlotte
- Xencor Investigative Site, Durham
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 3. aug. 2026 · NCT05433142Integrated Cancer Repository for Cancer Research
- Cape Fear Valley Health System, Fayetteville
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 19 til 110 · Alle kjønn · Oppdatert 29. jun. 2026 · NCT02012699A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
- Research Site, Durham
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 10. jun. 2026 · NCT06835569Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- Duke Cancer Center, Durham
- Carolina BioOncology Institute, Huntersville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 3. jun. 2026 · NCT06040541Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
- GSK Investigational Site, Durham
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 23. jan. 2026 · NCT05855200SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chapel Hill
- Massive Bio SYNERGY-AI site, Winston-Salem
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774Pilot Study for Colorectal Cancer and Advanced Adenoma Detection With the Mainz Biomed Colorectal Cancer Test
- Virtual Research Group, Morrisville
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 18 og eldre · Alle kjønn · Oppdatert 12. aug. 2025 · NCT06864338APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
- University of North Carolina, Chapel Hill
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 27. jun. 2025 · NCT03175224Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.